These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
494 related articles for article (PubMed ID: 17431185)
1. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185 [TBL] [Abstract][Full Text] [Related]
2. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Perez-Martinez P; Corella D; Shen J; Arnett DK; Yiannakouris N; Tai ES; Orho-Melander M; Tucker KL; Tsai M; Straka RJ; Province M; Kai CS; Perez-Jimenez F; Lai CQ; Lopez-Miranda J; Guillen M; Parnell LD; Borecki I; Kathiresan S; Ordovas JM Am J Clin Nutr; 2009 Jan; 89(1):391-9. PubMed ID: 19056598 [TBL] [Abstract][Full Text] [Related]
4. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Cardona F; Guardiola M; Queipo-Ortuño MI; Murri M; Ribalta J; Tinahones FJ Atherosclerosis; 2009 Sep; 206(1):148-52. PubMed ID: 19344899 [TBL] [Abstract][Full Text] [Related]
5. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects. Jang Y; Chae JS; Kim OY; Park HJ; Kim JY; Paik JK; Lee SH; Lee JH Atherosclerosis; 2010 Aug; 211(2):512-9. PubMed ID: 20392444 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Irvin MR; Kabagambe EK; Tiwari HK; Parnell LD; Straka RJ; Tsai M; Ordovas JM; Arnett DK Circ Cardiovasc Genet; 2010 Oct; 3(5):462-7. PubMed ID: 20729559 [TBL] [Abstract][Full Text] [Related]
7. Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T>C polymorphism and fasting triglyceride levels. Kim JY; Kim OY; Paik JK; Lee SH; Lee JH J Clin Lipidol; 2013; 7(2):94-101. PubMed ID: 23415427 [TBL] [Abstract][Full Text] [Related]
8. Comparison of low-fat meal and high-fat meal on postprandial lipemic response in non-obese men according to the -1131T>C polymorphism of the apolipoprotein A5 (APOA5) gene (randomized cross-over design). Kim JY; Kim OY; Koh SJ; Jang Y; Yun SS; Ordovas JM; Lee JH J Am Coll Nutr; 2006 Aug; 25(4):340-7. PubMed ID: 16943456 [TBL] [Abstract][Full Text] [Related]
9. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. Komurcu-Bayrak E; Onat A; Poda M; Humphries SE; Palmen J; Guclu F; Can G; Erginel-Unaltuna N Clin Chem Lab Med; 2008; 46(6):778-84. PubMed ID: 18601598 [TBL] [Abstract][Full Text] [Related]
10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Milosavljevic D; Griglio S; Le Naour G; Chapman MJ Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449 [TBL] [Abstract][Full Text] [Related]
11. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Niculescu LS; Vlădică M; Sima AV Biochem Biophys Res Commun; 2010 Jan; 391(1):587-91. PubMed ID: 19932084 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464 [TBL] [Abstract][Full Text] [Related]
14. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769 [TBL] [Abstract][Full Text] [Related]
15. Changes of plasma lipids during weight reduction in females depends on APOA5 variants. Suchanek P; Lorenzova A; Poledne R; Hubacek JA Ann Nutr Metab; 2008; 53(2):104-8. PubMed ID: 18946207 [TBL] [Abstract][Full Text] [Related]
16. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. OʼBrien SE; Schrodi SJ; Ye Z; Brilliant MH; Virani SS; Brautbar A J Cardiovasc Pharmacol; 2015 Aug; 66(2):183-8. PubMed ID: 25900265 [TBL] [Abstract][Full Text] [Related]
17. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537 [TBL] [Abstract][Full Text] [Related]
18. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Qi L; Liu S; Rifai N; Hunter D; Hu FB Atherosclerosis; 2007 May; 192(1):204-10. PubMed ID: 16781717 [TBL] [Abstract][Full Text] [Related]
19. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367 [TBL] [Abstract][Full Text] [Related]
20. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. Lai CQ; Corella D; Demissie S; Cupples LA; Adiconis X; Zhu Y; Parnell LD; Tucker KL; Ordovas JM Circulation; 2006 May; 113(17):2062-70. PubMed ID: 16636175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]